Enter inventor name

Dieter Seidelmann

This inventor holds 44 USPTO granted patents and 2 published patent applications, primarily in Beta-Carboline Derivatives. Top assignees: Schering Aktiengesellschaft, Novartis Ag, Schering Aktiengeseellschaft. Active years: 1978-2009.

USPTO Granted Patents = 44 (Patent Applications = 2)

% Patents Active = 81.8

Average Co-Inventor Count = 6.8

ph-index = 11

Forward Citations = 424(Granted Patents)

Company Filing History:

38 out of 1,384

Schering Aktiengesellschaft

Schering Aktiengeseellschaft

patent

4. 1 out of 1

Scnering Aktiengesellschaft

6. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1978-2009

Loading Chart...

Areas of Expertise:

VEGF Inhibitors

Beta-Carboline Derivatives

Pharmaceutical Agents

Azanthranyl Amides

Quinoxaline Derivatives

Anthranilic Acid Amides

Medicinal Compounds

Heteroaryloxy Compounds

Imidazole Derivatives

Psycho Tropic Compositions

Tranquilizers

Benzodiazepine Antagonists

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7479491 - Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors (2009-01-20),

2. 7122547 - Anthranilic acid amides and the use thereof as medicaments (2006-10-17),

3. 7081468 - Ortho-substituted anthranilic acid amides and their use as medicaments (2006-07-25),

4. 7012081 - Anthranyl amides and their use as medicaments (2006-03-14),

5. 7002022 - N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF (2006-02-21),

6. 6878720 - VEGF receptor tyrosine kinase inhibitors (2005-04-12),

7. 6818661 - Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors (2004-11-16),

8. 6448277 - VEGF receptor tyrosine kinase inhibitors (2002-09-10),

9. 6288065 - Quinoxaline-carboxylic acid derivatives (2001-09-11),

10. 6143733 - Quinoxalinedione derivatives, their production and use in pharmaceutical (2000-11-07),

11. 6136805 - Quinoxaline dione derivatives, their production and their use in (2000-10-24),

12. 6127368 - Anellated .beta.-carbolines (2000-10-03),

13. 6057304 - Quinoxaline-phosphonic acid derivatives (2000-05-02),

14. 5700808 - 5- or 6-substituted .beta.-carboline-3-carboxylic acid esters (1997-12-23),

15. 5698555 - Hetaryloxy-.beta.-carbolines, their production and use in pharmaceutical (1997-12-16),

Title: Dieter Seidelmann: Innovations in Medicinal Chemistry

Introduction

Dieter Seidelmann is a prominent inventor based in Berlin, Germany. With an impressive portfolio of 44 patents, he has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target persistent angiogenesis-related diseases.

Latest Patents

Among Dieter Seidelmann's recent inventions are two notable patents:

1. **Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors** - This invention involves substituted anthranylalkyl and -cycloalkyl amides of general formula (I). These compounds are specifically designed for use as medicaments to treat diseases characterized by persistent angiogenesis.

2. **Anthranilic acid amides and the use thereof as medicaments** - This patent focuses on anthranilic acid amides and their applications as medicaments for treating diseases triggered by persistent angiogenesis. Additionally, it includes the intermediate products involved in the production of these compounds.

Career Highlights

Dieter has built an extensive career, having worked for notable companies in the pharmaceutical industry, including Schering Aktiengesellschaft and Novartis AG. His experience in these organizations has greatly influenced his innovative efforts and contributions to drug development.

Collaborations

Throughout his career, Dieter has collaborated with esteemed colleagues such as Andreas Huth and Ralph Schmiechen. These collaborations have fostered an environment of creativity and innovation, enabling the development of groundbreaking medicinal formulas.

Conclusion

Dieter Seidelmann continues to be a leading figure in medicinal chemistry, with his patents reflecting his dedication to advancing healthcare solutions. His work not only highlights the importance of innovation in pharmaceuticals but also underscores the collaborative spirit that drives significant advancements in medical research.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]